Long-term management and results in heart transplant recipients.
This article reviews the evolution of therapeutic strategies for maintenance immunosuppression, and presents current approaches to prevention, treatment, and surveillance of acute rejection. Other major complications influencing mortality and morbidity are discussed; these include infection, cyclosporine nephrotoxicity, malignancy, and bone disease.
Valantine
H A
HA
Division of Cardiology, Stanford University School of Medicine, California.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001706:Biopsy; D003524:Cyclosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D006084:Graft Rejection; D016027:Heart Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009206:Myocardium / Q000473:pathology
D000911:Antibodies, Monoclonal; D003524:Cyclosporins; D007166:Immunosuppressive Agents